On the public citation graph
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
0 signed · 2045 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/archneur.58.6.961openalex-snapshot
Use of the Multiple Sclerosis Functional Composite as an Outcome Measure in a Phase 3 Clinical Trial
inferredcites →https://doi.org/10.1001/jamaneurol.2014.3537openalex-snapshot
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort
inferredcites →https://doi.org/10.1002/ana.21102openalex-snapshot
New natural history of interferon‐β–treated relapsing multiple sclerosis
inferredcites →https://doi.org/10.1002/ana.22366openalex-snapshot
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
inferredcites →https://doi.org/10.1002/ana.24009openalex-snapshot
Multiple sclerosis: Prospects and promise
inferredcites →https://doi.org/10.1002/ana.24747openalex-snapshot
Long‐term evolution of multiple sclerosis disability in the treatment era
inferredcites →https://doi.org/10.1002/ana.410430409openalex-snapshot
Multiple sclerosis: In situ evidence for antibody‐ and complement‐mediated demyelination
inferredcites →https://doi.org/10.1002/art.23732openalex-snapshot
Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study
inferredcites →https://doi.org/10.1002/ijc.21437openalex-snapshot
Cancer risk among patients with multiple sclerosis: A population‐based register study
inferredcites →https://doi.org/10.1006/nimg.2002.1040openalex-snapshot
Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis
inferredcites →https://doi.org/10.1007/s00415-005-5002-7openalex-snapshot
The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage
inferredcites →https://doi.org/10.1016/s0140-6736(11)61649-8openalex-snapshot
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
inferredcites →https://doi.org/10.1016/s0140-6736(12)61768-1openalex-snapshot
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
inferredcites →https://doi.org/10.1016/s1474-4422(07)70078-9openalex-snapshot
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
inferredcites →https://doi.org/10.1016/s1474-4422(11)70149-1openalex-snapshot
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
inferredcites →https://doi.org/10.1038/5532openalex-snapshot
Identification of autoantibodies associated with myelin damage in multiple sclerosis
inferredcites →https://doi.org/10.1038/nrneurol.2016.21openalex-snapshot
Disease-modifying therapies and infectious risks in multiple sclerosis
inferredcites →https://doi.org/10.1055/s-2007-1019124openalex-snapshot
The Immunology of Multiple Sclerosis
inferredcites →https://doi.org/10.1056/nejmoa0706383openalex-snapshot
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
inferredcites →https://doi.org/10.1056/nejmoa1606468openalex-snapshot
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
inferredcites →https://doi.org/10.1093/brain/awr182openalex-snapshot
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
inferredcites →https://doi.org/10.1093/brain/aws148openalex-snapshot
Cancer risk in multiple sclerosis: findings from British Columbia, Canada
inferredcites →https://doi.org/10.1111/ajt.12220openalex-snapshot
A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function
inferredcites →https://doi.org/10.1111/j.1750-3639.2004.tb00049.xopenalex-snapshot
Detection of Ectopic B‐cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis
inferredcites →https://doi.org/10.1126/scitranslmed.3008879openalex-snapshot
B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes
inferredcites →https://doi.org/10.1126/scitranslmed.3008930openalex-snapshot
Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis
inferredcites →https://doi.org/10.1126/scitranslmed.aab4176openalex-snapshot
Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy
inferredcites →https://doi.org/10.1136/jnnp-2011-301178openalex-snapshot
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
inferredcites →https://doi.org/10.1146/annurev.immunol.24.021605.090517openalex-snapshot
B CELL IMMUNOBIOLOGY IN DISEASE: Evolving Concepts from the Clinic
inferredcites →https://doi.org/10.1172/jci63842openalex-snapshot
B cell exchange across the blood-brain barrier in multiple sclerosis
inferredcites →https://doi.org/10.1177/1352458507077007openalex-snapshot
Neutralizing antibodies in MS therapy: reviewing the Rebif experience
inferredcites →https://doi.org/10.1177/1352458514561911openalex-snapshot
The Charcot Lecture | Beating MS: A story of B cells, with twists and turns
inferredcites →https://doi.org/10.1177/1756285612474333openalex-snapshot
Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges
inferredcites →https://doi.org/10.1177/1756285615601933openalex-snapshot
The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects
inferredcites →https://doi.org/10.1212/wnl.33.11.1444openalex-snapshot
Rating neurologic impairment in multiple sclerosis
inferredcites →https://doi.org/10.4049/jimmunol.180.1.361openalex-snapshot
Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice
inferredcites →https://doi.org/10.4161/mabs.22771openalex-snapshot
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
inferredcites →https://doi.org/10.4161/mabs.24108openalex-snapshot
Response to: Monoclonal antibodies targeting CD20
inferredcites →https://doi.org/10.7224/1537-2073.2014-030openalex-snapshot
Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS) Program
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1002/ana.27026openalex-extracted
Hospital‐Treated Infections and Risk of Disability Worsening in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/jama.2020.1522openalex-snapshot
Progress in Multiple Sclerosis Research
inferred← citeshttps://doi.org/10.1001/jama.2020.26858openalex-snapshot
Diagnosis and Treatment of Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.19766openalex-snapshot
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.38277openalex-snapshot
Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies
inferred← citeshttps://doi.org/10.1001/jamaneurol.2017.4011openalex-snapshot
Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/jamaneurol.2018.4239openalex-snapshot
Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/jamaneurol.2019.0522openalex-snapshot
Fulminant Hepatitis Associated With Echovirus 25 During Treatment With Ocrelizumab for Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/jamaneurol.2019.3365openalex-snapshot
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
inferred← citeshttps://doi.org/10.1001/jamaneurol.2020.1568openalex-snapshot
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
inferred← citeshttps://doi.org/10.1001/jamaneurol.2020.2950openalex-snapshot
Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/jamaneurol.2021.0405openalex-snapshot
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study
inferred← citeshttps://doi.org/10.1001/jamaneurol.2021.0627openalex-snapshot
Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
inferred← citeshttps://doi.org/10.1001/jamaneurol.2023.1542openalex-snapshot
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation
inferred← citeshttps://doi.org/10.1001/jamaneurol.2023.1625openalex-snapshot
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/jamaneurol.2023.2125openalex-snapshot
Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020
inferred← citeshttps://doi.org/10.1001/jamaneurol.2024.0017openalex-snapshot
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/jamaneurol.2024.0395openalex-snapshot
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS
inferred← citeshttps://doi.org/10.1001/jamaneurol.2024.1961openalex-snapshot
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/jamaneurol.2024.2920openalex-snapshot
Comorbidity and Disease Activity in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/jamaneurol.2026.0548openalex-snapshot
Interstitial Lung Disease as a Late Occurrence in Ocrelizumab-Treated Patients With Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/jamaneurol.2026.2500openalex-snapshot
Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/jamaneurol.2026.3507openalex-snapshot
Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/14651858.cd004192.pub4openalex-snapshot
Dietary interventions for multiple sclerosis-related outcomes
inferred← citeshttps://doi.org/10.1002/14651858.cd011381.pub3openalex-snapshot
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
inferred← citeshttps://doi.org/10.1002/14651858.cd012186.pub2openalex-snapshot
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis
inferred← citeshttps://doi.org/10.1002/14651858.cd013247.pub2openalex-snapshot
Ocrelizumab for multiple sclerosis
inferred← citeshttps://doi.org/10.1002/9781119564690.ch4openalex-snapshot
Major Classes of Biotherapeutics
inferred← citeshttps://doi.org/10.1002/9783527810697.ch7openalex-snapshot
Antiviral Targeting of the Complex Epstein Barr Virus Life Cycle
inferred← citeshttps://doi.org/10.1002/9783527814695.ch7openalex-snapshot
Ocrelizumab: A New Generation of anti‐ CD20 mAb for Treatment of Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/acn3.491openalex-snapshot
Infectious risk stratification in multiple sclerosis patients receiving immunotherapy
inferred← citeshttps://doi.org/10.1002/acn3.51111openalex-snapshot
Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
inferred← citeshttps://doi.org/10.1002/acn3.51282openalex-snapshot
Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population
inferred← citeshttps://doi.org/10.1002/acn3.51310openalex-snapshot
Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial
inferred← citeshttps://doi.org/10.1002/acn3.51510openalex-snapshot
Sustained immunotolerance in multiple sclerosis after stem cell transplant
inferred← citeshttps://doi.org/10.1002/acn3.51732openalex-snapshot
Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review
inferred← citeshttps://doi.org/10.1002/acn3.51745openalex-snapshot
Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
inferred← citeshttps://doi.org/10.1002/acn3.51965openalex-snapshot
Repeated iv anti‐CD20 treatment in multiple sclerosis: Long‐term effects on peripheral immune cell subsets
inferred← citeshttps://doi.org/10.1002/acn3.51996openalex-snapshot
Proteomic signatures of physical, cognitive, and imaging outcomes in multiple sclerosis
inferred← citeshttps://doi.org/10.1002/acn3.52167openalex-snapshot
Ocrelizumab alters the circulating metabolome in people with relapsing–remitting multiple sclerosis
inferred← citeshttps://doi.org/10.1002/acn3.640openalex-snapshot
NeurEx: digitalized neurological examination offers a novel high‐resolution disability scale
inferred← citeshttps://doi.org/10.1002/acn3.674openalex-snapshot
Retinal measurements predict 10‐year disability in multiple sclerosis
inferred← citeshttps://doi.org/10.1002/acn3.700openalex-snapshot
Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
inferred← citeshttps://doi.org/10.1002/acn3.70111openalex-snapshot
Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/acn3.70135openalex-snapshot
Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/acn3.70142openalex-snapshot
Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/acn3.70298openalex-snapshot
Shared Genetic Effects and Antagonistic Pleiotropy Between Multiple Sclerosis and Common Cancers
inferred← citeshttps://doi.org/10.1002/acn3.70302openalex-snapshot
Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/acn3.70483openalex-snapshot
Disease Course After Anti‐ CD20 Discontinuation in Secondary Progressive Multiple Sclerosis—A Multicenter Long‐Term Longitudinal Study
inferred← citeshttps://doi.org/10.1002/acn3.70497openalex-snapshot
Anti‐ CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non‐Active Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/acn3.792openalex-snapshot
Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model
inferred← citeshttps://doi.org/10.1002/adhm.202000164openalex-snapshot
Nano and Microparticle Emerging Strategies for Treatment of Autoimmune Diseases: Multiple Sclerosis and Type 1 Diabetes
inferred← citeshttps://doi.org/10.1002/ana.25119openalex-snapshot
B‐cell Therapy for Multiple Sclerosis: Entering an era
inferred← citeshttps://doi.org/10.1002/ana.25323openalex-snapshot
Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas
inferred← citeshttps://doi.org/10.1002/ana.25737openalex-snapshot
Real‐World Effectiveness of Initial Disease‐Modifying Therapies in Pediatric Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/ana.25770openalex-snapshot
SARS‐CoV ‐2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad
inferred← citeshttps://doi.org/10.1002/ana.25927openalex-snapshot
Role of B Cells in Multiple Sclerosis and Related Disorders
inferred← citeshttps://doi.org/10.1002/ana.26028openalex-snapshot
Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/ana.26154openalex-snapshot
Spinal Fluid Myeloid Microvesicles Predict Disease Course in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/ana.26155openalex-snapshot
Curing Multiple Sclerosis: How to Know When We're There
inferred← citeshttps://doi.org/10.1002/ana.26534openalex-snapshot
Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV ‐2 Vaccination Response in Patients with Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/ana.26751openalex-snapshot
Treatment Effect on Brain Atrophy Correlates with Treatment Effect on Cognition in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/ana.27012openalex-snapshot
COMBAT ‐ MS : A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
inferred← citeshttps://doi.org/10.1002/ana.27029openalex-snapshot
The Role of Chimeric Antigen Receptor T‐Cell Therapy in Immune‐Mediated Neurological Diseases
inferred← citeshttps://doi.org/10.1002/ana.27096openalex-snapshot
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/ana.27143openalex-snapshot
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab
inferred← citeshttps://doi.org/10.1002/ana.27165openalex-snapshot
Increased White Matter Aerobic Glycolysis in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/ana.27251openalex-snapshot
Detecting New Lesions Using a Large Language Model: Applications in Real‐World Multiple Sclerosis Datasets
inferred← citeshttps://doi.org/10.1002/ana.27270openalex-snapshot
New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond
inferred← citeshttps://doi.org/10.1002/ana.27281openalex-snapshot
Effect of Cumulative Exposure to Ocrelizumab on Memory B‐Cell Repopulation Dynamics in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/ana.78004openalex-snapshot
Phenotypic Changes in a Monocyte Cluster with High Interleukin‐1 Beta Expression during Long‐Term Anti‐ CD20 Therapy
inferred← citeshttps://doi.org/10.1002/ana.78033openalex-snapshot
Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence
inferred← citeshttps://doi.org/10.1002/ana.78086openalex-snapshot
Real‐World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease‐Modifying Therapy in Pediatric Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/ana.78286openalex-snapshot
Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study
inferred← citeshttps://doi.org/10.1002/ana.78290openalex-snapshot
Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES : A Single‐Arm Clinical Trial
inferred← citeshttps://doi.org/10.1002/bies.70118openalex-snapshot
The CNS Meninges and the Synovial Joint: Parallel Immunological Structures in Autoimmune Disease
inferred← citeshttps://doi.org/10.1002/bimj.202300387openalex-snapshot
Investigating the Heterogeneity of “Study Twins”
inferred← citeshttps://doi.org/10.1002/brb3.1068openalex-snapshot
Whole‐brain atrophy assessed by proportional‐ versus registration‐based pipelines from 3T MRI in multiple sclerosis
inferred← citeshttps://doi.org/10.1002/brb3.696openalex-snapshot
The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis
inferred← citeshttps://doi.org/10.1002/brb3.70326openalex-snapshot
Evolving Patterns of Initial RRMS Treatment in Finland (2013–2022): Insights From a Nationwide Multiple Sclerosis Register
inferred← citeshttps://doi.org/10.1002/brb3.71386openalex-snapshot
The Effect of Ocrelizumab on Anti‐JC Virus Antibody Index
inferred← citeshttps://doi.org/10.1002/cam4.1098openalex-snapshot
Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)
inferred← citeshttps://doi.org/10.1002/cpt.70352openalex-snapshot
Translating B‐Cell and Plasma‐Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap
inferred← citeshttps://doi.org/10.1002/cpz1.437openalex-snapshot
Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis, the Ottawa Protocol
inferred← citeshttps://doi.org/10.1002/cti2.1197openalex-snapshot
Narrowband UVB phototherapy reduces TNF production by B‐cell subsets stimulated via TLR7 from individuals with early multiple sclerosis
inferred← citeshttps://doi.org/10.1002/cti2.1295openalex-snapshot
Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells
inferred← citeshttps://doi.org/10.1002/ctm2.70178openalex-snapshot
Preclinical B cell depletion and safety profile of a brain‐shuttled crystallizable fragment‐silenced CD20 antibody
inferred← citeshttps://doi.org/10.1002/eji.201646485openalex-snapshot
Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis
inferred← citeshttps://doi.org/10.1002/eji.202048655openalex-snapshot
Attenuated immune control of Epstein–Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA‐DR15
inferred← citeshttps://doi.org/10.1002/eji.202149675openalex-snapshot
Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches
inferred← citeshttps://doi.org/10.1002/eji.202149757openalex-snapshot
Multiple sclerosis: Immunopathological heterogeneity and its implications
inferred← citeshttps://doi.org/10.1002/eji.202250033openalex-snapshot
Therapeutic targeting of gut‐originating regulatory B cells in neuroinflammatory diseases
inferred← citeshttps://doi.org/10.1002/eji.70153openalex-snapshot
Latent, Lytic, and Linked to Multiple Sclerosis—How EBV Drives Autoimmunity
inferred← citeshttps://doi.org/10.1002/glia.23529openalex-snapshot
Enforced microglial depletion and repopulation as a promising strategy for the treatment of neurological disorders
inferred← citeshttps://doi.org/10.1002/hbm.24510openalex-snapshot
Quantitative neuroimaging measures of myelin in the healthy brain and in multiple sclerosis
inferred← citeshttps://doi.org/10.1002/hsr2.1422openalex-snapshot
Comparison of recent updates in genetics, immunology, biomarkers, and neuroimaging of primary‐progressive and relapsing‐remitting multiple sclerosis and the role of ocrelizumab in the management of their refractory cases
inferred← citeshttps://doi.org/10.1002/hsr2.72142openalex-snapshot
Long‐Term Clinical and Psychological Efficacy and Safety of Ocrelizumab in People With Multiple Sclerosis: A Real‐World Longitudinal Study
inferred← citeshttps://doi.org/10.1002/jnr.24090openalex-snapshot
Modulating inflammation and neuroprotection in multiple sclerosis
inferred← citeshttps://doi.org/10.1002/jnr.24554openalex-snapshot
Dysfunctional RNA‐binding protein biology and neurodegeneration in experimental autoimmune encephalomyelitis in female mice
inferred← citeshttps://doi.org/10.1002/jnr.25129openalex-snapshot
Cell‐based experimental strategies for myelin repair in multiple sclerosis
inferred← citeshttps://doi.org/10.1002/jrsm.1301openalex-snapshot
A simple method for combining binomial counts or proportions with hazard ratios for evidence synthesis of time‐to‐event data
inferred← citeshttps://doi.org/10.1002/med.21973openalex-snapshot
Reconsidering the route of drug delivery in refractory multiple sclerosis: Toward a more effective drug accumulation in the central nervous system
inferred← citeshttps://doi.org/10.1002/med4.33openalex-snapshot
Meta‐analysis of the use of Ofatumumab in the treatment of relapsing‐remitting multiple sclerosis
inferred← citeshttps://doi.org/10.1002/mus.25973openalex-snapshot
B cells in the pathophysiology of myasthenia gravis
inferred← citeshttps://doi.org/10.1002/pds.5810openalex-snapshot
Do efficacy results obtained from randomized controlled trials translate to effectiveness data from observational studies for relapsing–remitting multiple sclerosis?
inferred← citeshttps://doi.org/10.1002/psb.1705openalex-snapshot
Ocrelizumab for relapsing or primary progressive MS
inferred← citeshttps://doi.org/10.1002/pst.1913openalex-snapshot
A simple test for the treatment effect in clinical trials with a sequential parallel comparison design and negative binomial outcomes
inferred← citeshttps://doi.org/10.1002/rcr2.70268openalex-snapshot
Secondary Organising Pneumonia Among Immunocompromised Multiple Sclerosis Patients Treated With Ocrelizumab Following COVID ‐19 Infection: Two Case Reports With Literature Review
inferred← citeshttps://doi.org/10.1002/wsbm.1583openalex-snapshot
Neurodegeneration in multiple sclerosis
inferred← citeshttps://doi.org/10.1007/978-1-0716-1213-2_19openalex-snapshot
Translational Aspects of Immunotherapeutic Targets in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/978-1-0716-3195-9_28openalex-snapshot
Machine Learning in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/978-1-4939-9465-6_11openalex-snapshot
Neuroprotection in Miscellaneous Neurological Disorders
inferred← citeshttps://doi.org/10.1007/978-3-030-03140-4_12openalex-snapshot
Noninfectious Uveitis: Emerging Therapies
inferred← citeshttps://doi.org/10.1007/978-3-030-10811-3_35openalex-snapshot
Drugs for Soft Tissue Autoimmune Disorders
inferred← citeshttps://doi.org/10.1007/978-3-030-19515-1_12openalex-snapshot
General Principles of Immunotherapy in Neurological Diseases
inferred← citeshttps://doi.org/10.1007/978-3-030-19515-1_2openalex-snapshot
Roles of Effector T Cells in Neurological Autoimmunity
inferred← citeshttps://doi.org/10.1007/978-3-030-21735-8_13openalex-snapshot
Systematic Understanding of Bioactive Lipids in Neuro-Immune Interactions: Lessons from an Animal Model of Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/978-3-030-28008-6_32openalex-snapshot
Multiple Sclerosis and the Heart
inferred← citeshttps://doi.org/10.1007/978-3-030-61883-4_1openalex-snapshot
Introduction to Neuroimmunology: What the Cerebrospinal Fluid Teaches Us About Diseases of the Central Nervous System
inferred← citeshttps://doi.org/10.1007/978-3-030-61883-4_31openalex-snapshot
Use of Disease-Modifying Therapies in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/978-3-031-24297-7_12-1openalex-snapshot
General Principles of Immunotherapy in Neurological Diseases
inferred← citeshttps://doi.org/10.1007/978-3-031-24297-7_2-1openalex-snapshot
Principles in Effector T Cells
inferred← citeshttps://doi.org/10.1007/978-3-031-43904-9_46openalex-snapshot
Improving Image-Based Precision Medicine with Uncertainty-Aware Causal Models
inferred← citeshttps://doi.org/10.1007/978-3-031-60006-7_12openalex-snapshot
General Principles of Immunotherapy in Neurological Diseases
inferred← citeshttps://doi.org/10.1007/978-3-031-60006-7_2openalex-snapshot
Principles in Effector T Cells
inferred← citeshttps://doi.org/10.1007/978-3-031-72384-1_38openalex-snapshot
Probabilistic Temporal Prediction of Continuous Disease Trajectories and Treatment Effects Using Neural SDEs
inferred← citeshttps://doi.org/10.1007/978-3-032-16128-4_6openalex-snapshot
Spatio-Temporal Conditional Diffusion Models for Forecasting Future Multiple Sclerosis Lesion Masks Conditioned on Treatments
inferred← citeshttps://doi.org/10.1007/978-3-032-39494-1_4openalex-snapshot
Treating MS Part II: Disease-Modifying Therapies
inferred← citeshttps://doi.org/10.1007/978-3-319-51220-4_2openalex-snapshot
Multiple Sclerosis: Clinical Features, Immunopathogenesis, and Treatment
inferred← citeshttps://doi.org/10.1007/978-3-319-65921-3_1openalex-snapshot
General Introduction: What Is Progressive Multiple Sclerosis?
inferred← citeshttps://doi.org/10.1007/978-3-319-65921-3_4openalex-snapshot
Mechanisms of Disease Progression
inferred← citeshttps://doi.org/10.1007/978-3-319-68038-5_21openalex-snapshot
Monoclonal Anti-CD20 (B-Cell) Antibody and Autoimmune Diseases
inferred← citeshttps://doi.org/10.1007/978-3-319-90305-7_32-1openalex-snapshot
Multiple Sclerosis and the Heart
inferred← citeshttps://doi.org/10.1007/978-3-319-92399-4_16openalex-snapshot
Considerable Therapeutic Strategies for Treatment of Genetic Defects Govern Neurovascular Disease
inferred← citeshttps://doi.org/10.1007/978-3-662-44768-0_160-1openalex-snapshot
Multiple Sklerose: Therapie
inferred← citeshttps://doi.org/10.1007/978-3-662-55530-9_1openalex-snapshot
Multiple Sklerose und andere autoimmune ZNS-Erkrankungen
inferred← citeshttps://doi.org/10.1007/978-3-662-59046-1_36openalex-snapshot
Pharmakologische Behandlung der multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/978-3-662-60676-6_160openalex-snapshot
Multiple Sklerose: Therapie
inferred← citeshttps://doi.org/10.1007/978-3-662-62168-4_33openalex-snapshot
Pharmakologische Behandlung der multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/978-3-662-63825-5_34openalex-snapshot
Pharmakologische Behandlung der multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/978-981-15-9038-2_4openalex-snapshot
Immunotherapy for Autoimmune Diseases
inferred← citeshttps://doi.org/10.1007/978-981-95-0520-3_4openalex-snapshot
Decoding Environmental Triggers: Advancing Therapeutic Strategies and Preventive Measures for Rheumatoid Arthritis, Type 1 Diabetes, and Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/978-981-95-5088-3_12openalex-snapshot
Evolving Pharmacotherapies Involving Neuroimmune Crosstalk
inferred← citeshttps://doi.org/10.1007/978-981-95-7490-2_7openalex-snapshot
Emergence of Targeted Drug Delivery in the Management of Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/978-981-97-0308-1_7openalex-snapshot
Targeted Therapy for Neurological Disorders Using Nanomaterial-Based Drug Delivery Vehicle
inferred← citeshttps://doi.org/10.1007/978-981-97-9495-9_8openalex-snapshot
Multiple Sclerosis and the Blood–Cerebrospinal Fluid Barrier
inferred← citeshttps://doi.org/10.1007/s00115-018-0542-0openalex-snapshot
Neues aus der Immuntherapie bei Multipler Sklerose
inferred← citeshttps://doi.org/10.1007/s00115-020-00937-6openalex-snapshot
Ocrelizumab zur Behandlung der Multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/s00115-021-01080-6openalex-snapshot
Krankheitsmodifizierende Therapie der sekundär progredienten Multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/s00115-021-01157-2openalex-snapshot
Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)
inferred← citeshttps://doi.org/10.1007/s00115-021-01176-zopenalex-snapshot
Immuntherapie und personalisierte Behandlung bei Multipler Sklerose
inferred← citeshttps://doi.org/10.1007/s00210-026-05579-0openalex-snapshot
Emerging therapeutic strategies in multiple sclerosis: a focus on innovative and targeted approaches
inferred← citeshttps://doi.org/10.1007/s00234-023-03189-8openalex-snapshot
Reliability of brain atrophy measurements in multiple sclerosis using MRI: an assessment of six freely available software packages for cross-sectional analyses
inferred← citeshttps://doi.org/10.1007/s00234-024-03483-zopenalex-snapshot
Correlation between MRI utilization and therapy switches in disease-modifying treatments for multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s00281-024-01034-5openalex-snapshot
Current advancements in cellular immunotherapy for autoimmune disease
inferred← citeshttps://doi.org/10.1007/s00393-020-00767-6openalex-snapshot
Biologika und „small molecules“ beim systemischen Lupus erythematodes
inferred← citeshttps://doi.org/10.1007/s00401-020-02204-zopenalex-snapshot
Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease
inferred← citeshttps://doi.org/10.1007/s00401-023-02552-6openalex-snapshot
IL-10-providing B cells govern pro-inflammatory activity of macrophages and microglia in CNS autoimmunity
inferred← citeshttps://doi.org/10.1007/s00415-017-8594-9openalex-snapshot
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
inferred← citeshttps://doi.org/10.1007/s00415-018-8812-0openalex-snapshot
Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
inferred← citeshttps://doi.org/10.1007/s00415-018-8830-yopenalex-snapshot
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
inferred← citeshttps://doi.org/10.1007/s00415-018-8996-3openalex-snapshot
Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients
inferred← citeshttps://doi.org/10.1007/s00415-018-9050-1openalex-snapshot
Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients
inferred← citeshttps://doi.org/10.1007/s00415-018-9070-xopenalex-snapshot
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study
inferred← citeshttps://doi.org/10.1007/s00415-018-9092-4openalex-snapshot
Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders
inferred← citeshttps://doi.org/10.1007/s00415-019-09180-9openalex-snapshot
Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study
inferred← citeshttps://doi.org/10.1007/s00415-019-09248-6openalex-snapshot
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s00415-019-09421-xopenalex-snapshot
Promoting remyelination in multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s00415-019-09563-yopenalex-snapshot
Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study
inferred← citeshttps://doi.org/10.1007/s00415-019-09565-wopenalex-snapshot
New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s00415-019-09690-6openalex-snapshot
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s00415-020-09816-1openalex-snapshot
Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapy
inferred← citeshttps://doi.org/10.1007/s00415-020-10023-1openalex-snapshot
Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort
inferred← citeshttps://doi.org/10.1007/s00415-020-10210-0openalex-snapshot
Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension
inferred← citeshttps://doi.org/10.1007/s00415-021-10744-xopenalex-snapshot
Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
inferred← citeshttps://doi.org/10.1007/s00415-021-10836-8openalex-snapshot
Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s00415-021-10956-1openalex-snapshot
Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod—potentials and risks of subsequent highly active agents
inferred← citeshttps://doi.org/10.1007/s00415-022-11009-xopenalex-snapshot
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study
inferred← citeshttps://doi.org/10.1007/s00415-022-11193-wopenalex-snapshot
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
inferred← citeshttps://doi.org/10.1007/s00415-022-11320-7openalex-snapshot
Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
inferred← citeshttps://doi.org/10.1007/s00415-022-11350-1openalex-snapshot
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
inferred← citeshttps://doi.org/10.1007/s00415-022-11405-3openalex-snapshot
Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives
inferred← citeshttps://doi.org/10.1007/s00415-023-11644-yopenalex-snapshot
Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing–remitting multiple sclerosis in Austria
inferred← citeshttps://doi.org/10.1007/s00415-023-11645-xopenalex-snapshot
Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment
inferred← citeshttps://doi.org/10.1007/s00415-023-11969-8openalex-snapshot
Multiple sclerosis: time for early treatment with high-efficacy drugs
showing the first 200 of 2006 · page through all 2006
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.